US FDA to discuss OTC switch for adapalene

19 February 2016 - Deborah Wilkes


An advisory committee to the US Food and Drug Administration (FDA) is set to consider Galderma's application to switch adapalene – the active ingredient of its acne medicine Differin – from prescription to OTC status.

Click tags below for more information on topics:


Annual Subscription Holder?

Sign in to continue reading.

Sign In

Back to Industry News

Share this page: